Relmada Therapeutics, Inc. (RLMD)

$19.11

-0.14 (-0.73%)
Rating:
Recommendation:
-
Symbol RLMD
Price $19.11
Beta 0.542
Volume Avg. 0.27M
Market Cap 573.124M
Shares () -
52 Week Range 15.735-35.35
1y Target Est -
DCF Unlevered RLMD DCF ->
DCF Levered RLMD LDCF ->
ROE -97.44% Strong Sell
ROA -63.45% Strong Sell
Operating Margin -
Debt / Equity 7.32% Neutral
P/E -
P/B 2.58 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest RLMD news


Mr. Sergio Traversa
Healthcare
Biotechnology
NASDAQ Global Select

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.